ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1989

Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –

Tadashi Okano1, Tatsuya Koike2, Masahiro Tada1, Kenji Mamoto3, Yuko Sugioka1, Atsuko Kamiyama4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, 2Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, 3Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Rheumatosurgery, Osaka City University Medical School, Osaka, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Bone density, bone metabolism, fractures, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is one of the causes for secondary osteoporosis. Osteoporosis as a multifactorial disease might be derived from comorbidity itself, poorer physical activity, treatment with glucocorticoids, or postmenopausal status. Accelerated generalized bone loss often leads to an increased risk of vertebral fractures. The purpose of this study is to determine the prevalence and the risk factors for vertebral fractures in patients with RA.

Methods:

We started a 10-year prospective cohort study named TOMORROW (TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOWer morbidity and mortality, clinical trial registration number: UMIN000003876) in 2010. This study included 208 patients with RA (biological agents, n = 112; conventional therapy, n = 96) and 205 age- and sex-matched volunteers (total, n = 413). We evaluated the prevalence of vertebral fractures using thoracolumbar spine X-rays and analyzed the factors associated with vertebral fractures. Evaluation of existing vertebral fractures was used for a quantitative assessment of each vertebra from T4 to L4 as a first assessment and a semiquantitative visual assessment of each vertebra considered existing vertebral fractures by first assessment.

Results:

The prevalence of vertebral fractures was 45.5% and 30% in the RA and volunteer groups, respectively. Significantly more RA patients than volunteers had semiquantitative (SQ) grade 2 or more (15.2% vs. 5%). Bone mineral density, urine pentosidine, homocysteine and bone specific alkaline phosphatase (BAP) significantly correlated with vertebral fractures among the patients and urinary pentosidine levels in the RA patients with fractures were significantly higher than without fractures. Patients using bisphosphonates was 33.3% in patients with rheumatoid arthritis. Bone mineral density was lower and more vertebral fractures was found in patients using bisphosphonates than in patients without bisphosphonates.

 

Vertebral fractures

Volunteers

(n = 205)

RA

(n = 208)

N = 0

70%

54.5%

N = 1

14.5%

10.1%

N = 2

8%

9.6%

N ≧ 3

7.5%

25.8%

SQ grade ≧ 2

5%

15.2%

Thoracic spine BMD

0.750±0.126

0.701±0.125

Lumbar spine BMD

0.930±0.163

0.896±0.164

Conclusion:

The incidence of vertebral fractures was higher in patients with RA than in volunteers. Bone quality markers and vertebral fractures are closely linked with RA. We will continue to prospectively investigate the incidence of new vertebral fractures and the progression of osteoporosis in patients with RA.


Disclosure:

T. Okano,
None;

T. Koike,

Chugai Pharmaceutical,

2,

Eli Lilly Japan,

8,

Novartis Pharmaceutical Corporation,

2,

Teijin Pharma,

8,

Bristol-Myers Squibb,

5,

Ono Pharmaceutical,

8,

Santen Pharmaceutical,

8,

Eisai,

8,

Abbott Japan,

8,

Mitsubishi Tanabe Pharma Corporation,

2,

Takeda Pharmaceutical,

8,

Astellas Pharma Inc.,

8,

Pfizer Japan Inc.,

8,

Janssen Pharmaceutical,

2,

Asahi Kasei Pharma Corporation,

8,

Daiichi Sankyo Company,

2;

M. Tada,
None;

K. Mamoto,
None;

Y. Sugioka,
None;

A. Kamiyama,
None;

H. Nakamura,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-vertebral-fractures-in-patients-with-rheumatoid-arthritis-the-tomorrow-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology